标题
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
作者
关键词
-
出版物
JOURNAL OF CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2022-10-18
DOI
10.1200/jco.22.01690
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A comprehensive framework for early-onset colorectal cancer research
- (2022) Cathy Eng et al. LANCET ONCOLOGY
- Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO
- (2022) Daniele Rossini et al. JOURNAL OF CLINICAL ONCOLOGY
- Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.
- (2022) Takayuki Yoshino et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer
- (2021) Timothy J. Iveson et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial
- (2021) François Quénet et al. LANCET ONCOLOGY
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
- (2021) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial
- (2021) Thierry Andre et al. LANCET ONCOLOGY
- The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors
- (2021) Benoit Rousseau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial
- (2021) Mary F. Mulcahy et al. JOURNAL OF CLINICAL ONCOLOGY
- Hepatectomy Followed by mFOLFOX6 Versus Hepatectomy Alone for Liver-Only Metastatic Colorectal Cancer (JCOG0603): A Phase II or III Randomized Controlled Trial
- (2021) Yukihide Kanemitsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Racial disparities in comprehensive biomarker testing and clinical trial enrollment among patients with metastatic colorectal cancer (mCRC).
- (2021) Lisa M. Hess et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update
- (2021) Nancy N. Baxter et al. JOURNAL OF CLINICAL ONCOLOGY
- Treating the Whole Patient With Cancer: The Critical Importance of Understanding and Addressing the Trajectory of Medical Financial Hardship
- (2021) K Robin Yabroff et al. JNCI-Journal of the National Cancer Institute
- S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer Patients
- (2021) Veena Shankaran et al. JNCI-Journal of the National Cancer Institute
- Outcomes Among Minority Patients with Metastatic Colorectal Cancer in a Safety-Net Healthcare System
- (2020) Kelsey Lau-Min et al. Clinical Colorectal Cancer
- Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review
- (2020) Rebecca C. Auer et al. EUROPEAN JOURNAL OF CANCER
- Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
- (2020) Chiara Cremolini et al. LANCET ONCOLOGY
- Cancer Disparities and Health Equity: A Policy Statement From the American Society of Clinical Oncology
- (2020) Manali I. Patel et al. JOURNAL OF CLINICAL ONCOLOGY
- Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
- (2020) David A. Palma et al. JOURNAL OF CLINICAL ONCOLOGY
- Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer
- (2020) Chiara Cremolini et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
- (2020) Thierry André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
- (2019) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimal Surveillance Frequency After CRS/HIPEC for Appendiceal and Colorectal Neoplasms: A Multi-institutional Analysis of the US HIPEC Collaborative
- (2019) Adriana C. Gamboa et al. ANNALS OF SURGICAL ONCOLOGY
- Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline
- (2019) Christopher Lieu et al. JOURNAL OF CLINICAL ONCOLOGY
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
- (2019) Scott Kopetz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-effectiveness analysis of selective first-line use of biologics for unresectable RAS wild-type left-sided metastatic colorectal cancer
- (2019) W. W.L. Wong et al. Current Oncology
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)
- (2019) Dominik P. Modest et al. JOURNAL OF CLINICAL ONCOLOGY
- O-023FOLFOX/bevacizumab +/- irinotecan in advanced colorectal cancer (CHARTA): Long term outcome
- (2018) H Schmoll et al. ANNALS OF ONCOLOGY
- The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis
- (2018) Domenico Ciliberto et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Stereotactic Body Radiotherapy (SBRT) for liver metastasis – clinical outcomes from the international multi-institutional RSSearch® Patient Registry
- (2018) Anand Mahadevan et al. Radiation Oncology
- Stereotactic body radiotherapy for colorectal cancer liver metastases: A systematic review
- (2018) Fausto Petrelli et al. RADIOTHERAPY AND ONCOLOGY
- Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial
- (2018) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI‐Bevacizumab Versus FOLFOX‐Bevacizumab for Metastatic Colorectal Cancer (STEAM)
- (2018) Herbert I. Hurwitz et al. ONCOLOGIST
- The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials
- (2017) Julian Walter Holch et al. EUROPEAN JOURNAL OF CANCER
- Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy
- (2017) Paola Ulivi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer
- (2017) Alan P. Venook et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline
- (2017) Timothy Gilligan et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials
- (2017) Harpreet S Wasan et al. LANCET ONCOLOGY
- Integration of Palliative Care Into Standard Oncology Care: ASCO Clinical Practice Guideline Update Summary
- (2017) Betty R. Ferrell et al. Journal of Oncology Practice
- Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
- (2016) D. P. Modest et al. ANNALS OF ONCOLOGY
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
- (2016) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received
- (2016) Lowell E. Schnipper et al. JOURNAL OF CLINICAL ONCOLOGY
- What are the barriers faced by medical oncologists in initiating discussion of palliative care? A qualitative study in Flanders, Belgium
- (2016) M. Horlait et al. SUPPORTIVE CARE IN CANCER
- Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015 Summary
- (2016) Carmen J. Allegra et al. Journal of Oncology Practice
- American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
- (2015) Lowell E. Schnipper et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
- (2015) Chiara Cremolini et al. LANCET ONCOLOGY
- Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial
- (2014) T. Gruenberger et al. ANNALS OF ONCOLOGY
- PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
- (2014) Lee S. Schwartzberg et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
- (2014) Volker Heinemann et al. LANCET ONCOLOGY
- Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
- (2014) Fotios Loupakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
- (2013) Stacie B. Dusetzina et al. JOURNAL OF CLINICAL ONCOLOGY
- Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial
- (2013) Bernard Nordlinger et al. LANCET ONCOLOGY
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-Effectiveness Analysis of Screening for KRAS and BRAF Mutations in Metastatic Colorectal Cancer
- (2012) Ajay S. Behl et al. JNCI-Journal of the National Cancer Institute
- GRADE guidelines: 3. Rating the quality of evidence
- (2011) Howard Balshem et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Building better guidelines with BRIDGE-Wiz: development and evaluation of a software assistant to promote clarity, transparency, and implementability
- (2011) Richard N Shiffman et al. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
- Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions
- (2011) Sonya Blesser Streeter et al. Journal of Oncology Practice
- Socio-economic disparities in access to treatment and their impact on colorectal cancer survival
- (2010) C. Lejeune et al. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
- Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
- (2009) M Koopman et al. BRITISH JOURNAL OF CANCER
- American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
- (2009) Neal J. Meropol et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- 8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer
- (2008) Vic J. Verwaal et al. ANNALS OF SURGICAL ONCOLOGY
- Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials
- (2008) Emmanuel Mitry et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More